Bio-Techne Corporation TECH
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +23.55%
- 1 year
- +19.19%
- Open
- 72.72
- Prev close
- 72.71
- Mkt cap
- 11.41B
- Vol
- 2.57M
- Avg vol
- 2.84M
- EPS
- 1.16
- P/E
- 62.64
- Div yield
- 0.44%
More statistics
- Low
- 72.66
- High
- 72.73
- Forward P/E
- 31.44
- Beta
- 1.29
- Short ratio
- 2.42
- Inst. own
- 112.55%
- Dividend
- 0.32
- Ex-div date
- Aug 23, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 72.44
- 200-d avg
- 63.13
- 1y target
- 70.50
News
4 days ago seekingalpha.com
Conestoga SMid Cap Composite Q3 2026 Portfolio Activity
We initiated a position in Allegro because vehicle electrification, driver-assistance systems and other electronic features are increasing chip content per vehicle. We initiated a position in…
2 weeks ago globenewswire.com
Press release: CMB.TECH fleet update
Antwerp, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold one Suezmax, generating a…
3 weeks ago globenewswire.com
CMB.TECH SPECIAL GENERAL MEETING RESULTS
Antwerp, Oct. 08, 2026 (GLOBE NEWSWIRE) -- ANTWERP, Belgium, 8 October 2026, 15:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs:…
-
3 weeks ago benzinga.com
Bio-Techne Opens New Bristol Facility
Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applicationsNew Bristol facility expands GMP small molecule production capacity and complements recent…
3 weeks ago prnewswire.com
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications New Bristol facility expands GMP small molecule production capacity and complements recent…
1 month ago zacks.com
INCY or TECH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
1 month ago prnewswire.com
INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE
(CSE: URAI / OTC: URAIF / FSE: 3QG0) investor@inturai.com DomeCommand, the drone command-and-control platform the Company recently acquired, won first and third place in the two-day team integration…
1 month ago defenseworld.net
Bio-Techne (NASDAQ:TECH) Reaches New 52-Week High – Time to Buy?
Shares of Bio-Techne Corp (NASDAQ: TECH - Get Free Report) hit a new 52-week high on Monday. The company traded as high as $72.70 and last traded at $72.70, with a volume of 2660 shares trading…
1 month ago newsfilecorp.com
Zhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business
KEY HIGHLIGHTS Strategic Acquisition: Zhibao Technology Inc. (NASDAQ: ZBAO) ("Zhibao," "we," or the "Company") has entered into a definitive Merger and Acquisition Agreement dated September 28, 2026,…
-
1 month ago benzinga.com
Bio-Techne Receives Shareholders' Approval For Proposed Acquisition By Merck KGaA
Bio-Techne Corporation (NASDAQ:TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the…
1 month ago prnewswire.com
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne…
1 month ago prnewswire.com
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across the DACH and broader EMEA…
1 month ago zacks.com
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
1 month ago gurufocus.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Looming Merger Shareholder Vote - AUUD, TECH, CZR and CBAN
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Looming Merger Shareholder Vote - AUUD, TECH, CZR and CBAN PR Newsw
1 month ago seekingalpha.com
CMB.TECH: Updates From Our Top Shipping Pick Of 2026
CMB.TECH delivered a 134% return in under a year, driven by a strategic dry bulk focus and strong tanker markets. I recently interviewed the CEO and CFO to get updates on the dry bulk industry and…
1 month ago globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
1 month ago globenewswire.com
PRESS RELEASE: CMB.TECH announces special general meeting on 8 October 2026
ANTWERP, Belgium, 8 September 2026, 08:00 a.m. CET – CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) (NYSE: CMBT, Euronext Brussels: CMBT en Euronext Oslo Børs: CMBTO) invites…
-
2 months ago benzinga.com
Bio-Techne Announces SBTi Validation Of 70% Scope 1 & 2 Emissions Reduction Target By FY2031 And Supplier Engagement Commitment, Reporting Significant Operational Emissions Cuts In FY2026
Fiscal 2026 highlights:Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targetsMarket-based Scope 1 and 2 emissions reduced 49% year-over-yearMore…
2 months ago prnewswire.com
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More…
2 months ago seekingalpha.com
CMB.TECH: Q2 Was Strong, But Valuation Looks Full (Downgrade)
CMB.TECH (CMBT) shows improved earnings quality as core shipping EBITDA rises despite reduced ship sales. Q2 revenue and EBITDA surged, but backlog growth stalled, raising concerns about long-term…
2 months ago seekingalpha.com
CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript
CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
CMB.TECH Q2 Earnings Call Highlights
CMB.TECH NYSE: CMBT reported second-quarter 2026 net profit of $364.4 million, supported by revenue of more than $700 million and $127 million in gains from vessel sales, as shipping markets remained…
2 months ago globenewswire.com
CMB.TECH ANNOUNCES Q2 2026 RESULTS
ANTWERP, Belgium, 27 August 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today…
-
2 months ago benzinga.com
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
-
2 months ago benzinga.com
Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate
Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 1.89 percent decrease over earnings of $0.53 per share from the same period…
3 months ago benzinga.com
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
-
3 months ago benzinga.com
RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73
RBC Capital analyst Dan Leonard downgrades Bio-Techne (NASDAQ:TECH) from Outperform to Sector Perform and raises the price target from $62 to $73.
-
4 months ago benzinga.com
TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73
TD Cowen analyst Kyle Boucher downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold and raises the price target from $65 to $73.
-
4 months ago benzinga.com
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.
-
4 months ago benzinga.com
Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Stephens & Co. analyst Steven Etoch downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $68 to $73.
-
4 months ago benzinga.com
Baird Maintains Neutral on Bio-Techne, Raises Price Target to $73
Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Neutral and raises the price target from $49 to $73.
-
4 months ago benzinga.com
Bio-Techne To Pay Termination Fee Of $230.5M To Merck KGaA In Event That Deal Isn't Consummated; Merck KGaA To Pay Fee Of $576.1M If Deal Terminated
Termination Fees The Company will be required to pay to Parent a termination fee equal to $230,455,000 (the "Company Termination Fee"): · If (A) the Merger Agreement is validly terminated (i) by…
4 months ago benzinga.com
Micron Rallies 15%, Apple Sinks 6% On Memory Costs: Stock Market Today
Micron's blowout earnings powered memory and chip stocks higher, but the broad stock market rally stalled by midday as S&P 500 slipped.
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
4 months ago benzinga.com
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.
4 months ago benzinga.com
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
Merck KGaA is acquiring Bio-Techne in an $11.3B all-cash deal to expand its life science, diagnostics, and bioprocessing footprint.
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…
-
4 months ago benzinga.com
CORRECTION: Germany's Merck KGaA To Acquire Bio-Techne At $73 Per Share In Cash At EV $11.3B; Deal Expected To Be Immediately Sales Accretive And EBITDA Pre Margin Post-Closing And EPS Pre Accretive By Year 3 Post-Closing
Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ:TECH), a Minneapolis-based global provider of life science tools, analytical technologies,…
-
4 months ago benzinga.com
'Activist Investor Ananym Urges Bio-Techne to Consider Selling' - Bloomberg News
https://www.bloomberg.com/news/articles/2026-06-15/activist-investor-ananym-urges-bio-techne-to-consider-selling
-
4 months ago benzinga.com
Piper Sandler Initiates Coverage On Bio-Techne with Neutral Rating, Announces Price Target of $65
Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne (NASDAQ:TECH) with a Neutral rating and announces Price Target of $65.
-
5 months ago benzinga.com
Bio‑Techne And Refeyn Launch An Integrated Workflow To Characterize Charge And Size Variants In Bispecific Antibodies And Biosimilars
By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn's TwoMP mass photometry platform, researchers can directly correlate charge…
-
5 months ago benzinga.com
RBC Capital Reinstates Outperform on Bio-Techne, Announces $62 Price Target
RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ:TECH) with a Outperform and announces $62 price target.
-
5 months ago benzinga.com
Citigroup Maintains Buy on Bio-Techne, Lowers Price Target to $70
Citigroup analyst Patrick Donnelly maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $80 to $70.
-
5 months ago benzinga.com
Wells Fargo Maintains Overweight on Bio-Techne, Lowers Price Target to $62
Wells Fargo analyst Brandon Couillard maintains Bio-Techne (NASDAQ:TECH) with a Overweight and lowers the price target from $76 to $62.
-
5 months ago benzinga.com
Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $50
Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and lowers the price target from $54 to $50.
5 months ago benzinga.com
S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today
U.S. stocks hit records as Trump's Iran memo sinks oil 6%, AMD soars 17% on data-center beat.
5 months ago benzinga.com
Bio-Techne Q3 2026 Earnings Call: Complete Transcript
Bio-Techne Q3 2026 Earnings Call: Complete Transcript
-
5 months ago benzinga.com
Bio-Techne Q3 Adj. EPS $0.53 Misses $0.54 Estimate, Sales $311.415M Miss $317.093M Estimate
Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.53 per share which missed the analyst consensus estimate of $0.54 by 1.85 percent. This is a 5.36 percent decrease over earnings of $0.56…
-
6 months ago benzinga.com
Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $54
Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and lowers the price target from $68 to $54.